Moderna, Inc. Q3 2026 Earnings Call Summary

Strategic Pivot to Oncology and Diversified Respiratory Growth

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Management attributed the 29% year-over-year revenue growth to a combination of increased mNEXSPIKE adoption in the U.S. and the successful execution of strategic partnerships in the U.K. and Canada.

• The company achieved a return to profitability with $200 million in net income, driven by what management described as 'financial discipline' and a 10% reduction in cash costs compared to the previous year.

• The Phase 3 Intismeran results were framed as a 'landmark' milestone, representing the first individualized cancer therapy to demonstrate a significant clinical benefit over KEYTRUDA alone in adjuvant melanoma.

• Moderna is intentionally diversifying its portfolio beyond COVID-19, now boasting five approved infectious disease products including the first mRNA-based influenza vaccine to reach the market.

• The return of Juan Andres to the executive committee is a strategic move to leverage his experience in scaling manufacturing networks as the company prepares for the next phase of oncology growth.

• Management emphasized that the 42% reduction in risk of recurrence or death in the melanoma trial validates the mRNA platform's ability to generate neoantigen-specific T-cell responses.

Raised Revenue Outlook and Oncology Submission Timelines

• Full-year 2026 revenue growth guidance was increased to a range of 15% to 25%, up from the previous framework of up to 10%, based on strong demand and visibility into Q4 shipments.

• Management expects to submit the Biologics License Application (BLA) for Intismeran in melanoma by the end of 2026, with a goal of achieving regulatory approval in 2027.

• The financial framework for 2026 assumes a $200 million reduction in R&D expenses due to the wind-down of infectious disease studies and continued operational efficiencies.

• Upcoming clinical milestones include an event-driven Phase 2 readout for renal cell carcinoma expected in late 2026 or early 2027 and a registrational readout for propionic acidemia.

• Future growth strategy remains anchored in geographic expansion, particularly in Europe and Latin America, and the transition of the oncology pipeline toward commercialization.

Capital Allocation and Pipeline Adjustments

• The company raised $3 billion through a 0% convertible note to secure long-term capital on attractive terms specifically to fund the growth of the oncology business.

• Management decided to pause enrollment for the norovirus vaccine program (mRNA-1403) after it failed to meet statistical criteria for early success at an interim analysis.

• A $950 million litigation settlement payment was finalized during the quarter, which management noted as a primary driver for the seasonal impact on working capital.

• The decision to initiate a pivotal trial for methylmalonic acidemia (MMA) has been deferred until after the results of the propionic acidemia (PA) readout are available.